SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Byrd, J. C. Articles by Reed, J. C. Search for Related Content PubMed PubMed Citation Articles by Byrd, J. C. Articles by Reed, J. C. Related Collections Neoplasia Apoptosis Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 February 2002, Vol. 99, No. 3, pp. 1038-1043 NEOPLASIA The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction John C. Byrd, Shinichi Kitada, Ian W. Flinn, Jennifer L. Aron, Michael Pearson, David Lucas, and John C. Reed From the Division of Hematology-Oncology, The Ohio State University, Columbus; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore, MD; and Burnham Institute, Cancer Research Center, La Jolla, CA. Rituximab is a chimeric monoclonal antibody directed at CD20 with significant activity in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). A variety of pathways of tumor cytotoxicity different from cytotoxic chemotherapy have been proposed for this therapeutic antibody including antibody-dependent cellular cytotoxicity and complement-mediated cell lysis. This report describes that a proportion of patients with CLL receiving rituximab treatment have in vivo activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP) cleavage in blood leukemia cells immediately following infusion of rituximab. This suggests that apoptosis using a pathway similar to fludarabine and other chemotherapeutic agents is intricately involved in the blood elimination of tumor cells after rituximab treatment. Patients having caspase-3 activation and PARP cleavage in vivo had a significantly lower blood leukemia cell count after treatment as compared to those without caspase activation. Significant down-modulation of the antiapoptotic proteins XIAP and Mcl-1 was also noted, possibly explaining in part how rituximab sensitizes CLL cells to the cytotoxic effect of chemotherapy in vivo. These findings suggest that the therapeutic benefit of antibody-based therapy in vivo for patients with CLL depends in part on induction of apoptosis and provides another area of focus for studying mechanisms of antibody-resistance in neoplastic cells. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. Mishima, N. Sugimura, Y. Matsumoto-Mishima, Y. Terui, K. Takeuchi, S. Asai, D. Ennishi, H. Asai, M. Yokoyama, K. Kojima, et al. An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy Clin. Cancer Res., May 15, 2009; 15(10): 3624 - 3632. [Abstract] [Full Text] [PDF] S. P. Treon, A. R. Branagan, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, B. Turnbull, P. Wasi, C. Emmanouilides, S. R. Frankel, A. Lister, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia Blood, April 16, 2009; 113(16): 3673 - 3678. [Abstract] [Full Text] [PDF] S. Dalle, S. Dupire, S. Brunet-Manquat, L. Reslan, A. Plesa, and C. Dumontet In vivo Model of Follicular Lymphoma Resistant to Rituximab Clin. Cancer Res., February 1, 2009; 15(3): 851 - 857. [Abstract] [Full Text] [PDF] E. Racila, B. K. Link, W.-K. Weng, T. E. Witzig, S. Ansell, M. J. Maurer, J. Huang, C. Dahle, A. Halwani, R. Levy, et al. A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma Clin. Cancer Res., October 15, 2008; 14(20): 6697 - 6703. [Abstract] [Full Text] [PDF] A. Mankai, A. Bordron, Y. Renaudineau, C. Martins-Carvalho, S. Takahashi, I. Ghedira, C. Berthou, and P. Youinou Purine-Rich Box-1-Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells Cancer Res., September 15, 2008; 68(18): 7512 - 7519. [Abstract] [Full Text] [PDF] X. Zhou, W. Hu, and X. Qin The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy Oncologist, September 1, 2008; 13(9): 954 - 966. [Abstract] [Full Text] [PDF] P. V. Beum, M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. H. I. Parren, J. G. J. van de Winkel, and R. P. Taylor Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis J. Immunol., July 1, 2008; 181(1): 822 - 832. [Abstract] [Full Text] [PDF] C. A. Walshe, S. A. Beers, R. R. French, C. H. T. Chan, P. W. Johnson, G. K. Packham, M. J. Glennie, and M. S. Cragg Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling J. Biol. Chem., June 20, 2008; 283(25): 16971 - 16984. [Abstract] [Full Text] [PDF] N. I. Pathan, P. Chu, K. Hariharan, C. Cheney, A. Molina, and J. Byrd Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines Blood, February 1, 2008; 111(3): 1594 - 1602. [Abstract] [Full Text] [PDF] E. Bremer, B. ten Cate, D. F. Samplonius, N. Mueller, H. Wajant, A. J. Stel, M. Chamuleau, A. A. van de Loosdrecht, J. Stieglmaier, G. H. Fey, et al. Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists Cancer Res., January 15, 2008; 68(2): 597 - 604. [Abstract] [Full Text] [PDF] P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab Cancer Res., November 1, 2007; 67(21): 10556 - 10563. [Abstract] [Full Text] [PDF] A. P. Kater, M. H. J. van Oers, and T. J. Kipps Cellular immune therapy for chronic lymphocytic leukemia Blood, October 15, 2007; 110(8): 2811 - 2818. [Abstract] [Full Text] [PDF] X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical Blood, October 1, 2007; 110(7): 2569 - 2577. [Abstract] [Full Text] [PDF] S.-R. A. Hussain, C. M. Cheney, A. J. Johnson, T. S. Lin, M. R. Grever, M. A. Caligiuri, D. M. Lucas, and J. C. Byrd Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity Clin. Cancer Res., April 1, 2007; 13(7): 2144 - 2150. [Abstract] [Full Text] [PDF] R. Nimmanapalli, M.-A. Lyu, M. Du, M. J. Keating, M. G. Rosenblum, and V. Gandhi The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells Blood, March 15, 2007; 109(6): 2557 - 2564. [Abstract] [Full Text] [PDF] A. J. Stel, B. ten Cate, S. Jacobs, J. W. Kok, D. C. J. Spierings, M. Dondorff, W. Helfrich, H. C. Kluin-Nelemans, L. F. M. H. de Leij, S. Withoff, et al. Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis J. Immunol., February 15, 2007; 178(4): 2287 - 2295. [Abstract] [Full Text] [PDF] C. Bello and E. M. Sotomayor Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond Hematology, January 1, 2007; 2007(1): 233 - 242. [Abstract] [Full Text] [PDF] K. D. Khan, C. Emmanouilides, D. M. Benson Jr., D. Hurst, P. Garcia, G. Michelson, S. Milan, A. K. Ferketich, L. Piro, J. P. Leonard, et al. A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma Clin. Cancer Res., December 1, 2006; 12(23): 7046 - 7053. [Abstract] [Full Text] [PDF] J. A. Bowles, S.-Y. Wang, B. K. Link, B. Allan, G. Beuerlein, M.-A. Campbell, D. Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab Blood, October 15, 2006; 108(8): 2648 - 2654. [Abstract] [Full Text] [PDF] J. L. Teeling, W. J. M. Mackus, L. J. J. M. Wiegman, J. H. N. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 J. Immunol., July 1, 2006; 177(1): 362 - 371. [Abstract] [Full Text] [PDF] M. Alfonso-Perez, S. Lopez-Giral, N. E. Quintana, J. Loscertales, P. Martin-Jimenez, and C. Munoz Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia J. Leukoc. Biol., June 1, 2006; 79(6): 1157 - 1165. [Abstract] [Full Text] [PDF] B. F. Israel, M. Gulley, S. Elmore, S. Ferrini, W.-h. Feng, and S. C. Kenney Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas Mol. Cancer Ther., December 1, 2005; 4(12): 2037 - 2044. [Abstract] [Full Text] [PDF] E A Clark and J A Ledbetter How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv77 - iv80. [Abstract] [Full Text] [PDF] A. P. Kater, F. Dicker, M. Mangiola, K. Welsh, R. Houghten, J. Ostresh, A. Nefzi, J. C. Reed, C. Pinilla, and T. J. Kipps Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis Blood, September 1, 2005; 106(5): 1742 - 1748. [Abstract] [Full Text] [PDF] N. Zhang, L. A. Khawli, P. Hu, and A. L. Epstein Generation of Rituximab Polymer May Cause Hyper-Cross-linking-Induced Apoptosis in Non-Hodgkin's Lymphomas Clin. Cancer Res., August 15, 2005; 11(16): 5971 - 5980. [Abstract] [Full Text] [PDF] J. M. Pagel, C. Laugen, L. Bonham, R. C. Hackman, D. M. Hockenbery, R. Bhatt, D. Hollenback, H. Carew, J. W. Singer, and O. W. Press Induction of Apoptosis Using Inhibitors of Lysophosphatidic Acid Acyltransferase-{beta} and Anti-CD20 Monoclonal Antibodies for Treatment of Human Non-Hodgkin's Lymphomas Clin. Cancer Res., July 1, 2005; 11(13): 4857 - 4866. [Abstract] [Full Text] [PDF] T. S. Lin, M. R. Grever, and J. C. Byrd Changing the Way We Think About Chronic Lymphocytic Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4009 - 4012. [Full Text] [PDF] K. Balakrishnan, C. M. Stellrecht, D. Genini, M. Ayres, W. G. Wierda, M. J. Keating, L. M. Leoni, and V. Gandhi Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP Blood, June 1, 2005; 105(11): 4455 - 4462. [Abstract] [Full Text] [PDF] O. Berezovskaya, A. D. Schimmer, A. B. Glinskii, C. Pinilla, R. M. Hoffman, J. C. Reed, and G. V. Glinsky Increased Expression of Apoptosis Inhibitor Protein XIAP Contributes to Anoikis Resistance of Circulating Human Prostate Cancer Metastasis Precursor Cells Cancer Res., March 15, 2005; 65(6): 2378 - 2386. [Abstract] [Full Text] [PDF] M.S. Czuczman, A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson, Z.P. Bernstein, P. McCarthy, A. Alam, F. Hernandez-Ilizaliturri, et al. Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma J. Clin. Oncol., February 1, 2005; 23(4): 694 - 704. [Abstract] [Full Text] [PDF] M. L. Palomba, W. K. Roberts, T. Dao, G. Manukian, J. A. Guevara-Patino, J. D. Wolchok, D. A. Scheinberg, and A. N. Houghton CD8+ T-Cell-Dependent Immunity Following Xenogeneic DNA Immunization against CD20 in a Tumor Challenge Model of B-Cell Lymphoma Clin. Cancer Res., January 1, 2005; 11(1): 370 - 379. [Abstract] [Full Text] [PDF] J. W. Friedberg Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy Hematology, January 1, 2005; 2005(1): 329 - 334. [Abstract] [Full Text] [PDF] J. P. Leonard Targeting CD20 in Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and the Use of Radioimmunoconjugates Hematology, January 1, 2005; 2005(1): 335 - 339. [Abstract] [Full Text] [PDF] M. R. Smith, F. Jin, and I. Joshi Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts Mol. Cancer Ther., December 1, 2004; 3(12): 1693 - 1699. [Abstract] [Full Text] [PDF] G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny From the bench to the bedside: ways to improve rituximab efficacy Blood, November 1, 2004; 104(9): 2635 - 2642. [Abstract] [Full Text] [PDF] M. S. Cragg, M. B. Bayne, A. L. Tutt, R. R. French, S. Beers, M. J. Glennie, and T. M. Illidge A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells Blood, October 15, 2004; 104(8): 2540 - 2542. [Abstract] [Full Text] [PDF] C. F. Eisenbeis, A. Grainger, B. Fischer, R. A. Baiocchi, L. Carrodeguas, S. Roychowdhury, L. Chen, A. L. Banks, T. Davis, D. Young, et al. Combination Immunotherapy of B-Cell Non-Hodgkin's Lymphoma with Rituximab and Interleukin-2: A Preclinical and Phase I Study Clin. Cancer Res., September 15, 2004; 10(18): 6101 - 6110. [Abstract] [Full Text] [PDF] J. L. Teeling, R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. H. I. Parren, C. E. Hack, M. Dechant, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood, September 15, 2004; 104(6): 1793 - 1800. [Abstract] [Full Text] [PDF] Y. K. Lee, N. D. Bone, A. K. Strege, T. D. Shanafelt, D. F. Jelinek, and N. E. Kay VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia Blood, August 1, 2004; 104(3): 788 - 794. [Abstract] [Full Text] [PDF] A. J. Olszewski and M. L. Grossbard Empowering Targeted Therapy: Lessons from Rituximab Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30. [Abstract] [Full Text] [PDF] S. Kitada and J. C. Reed MCL-1 Promoter Insertions Dial-Up Aggressiveness of Chronic Leukemia J Natl Cancer Inst, May 5, 2004; 96(9): 642 - 643. [Full Text] [PDF] A. K. Gopal, J. M. Pagel, N. Hedin, and O. W. Press Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism Blood, May 1, 2004; 103(9): 3516 - 3520. [Abstract] [Full Text] [PDF] M. S. Cragg and M. J. Glennie Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents Blood, April 1, 2004; 103(7): 2738 - 2743. [Abstract] [Full Text] [PDF] A. D. Kennedy, P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia J. Immunol., March 1, 2004; 172(5): 3280 - 3288. [Abstract] [Full Text] [PDF] A. P. Mone, P. Huang, H. Pelicano, C. M. Cheney, J. M. Green, J. Y. Tso, A. J. Johnson, S. Jefferson, T. S. Lin, and J. C. Byrd Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells Blood, March 1, 2004; 103(5): 1846 - 1854. [Abstract] [Full Text] [PDF] S. S. Farag, I. W. Flinn, R. Modali, T. A. Lehman, D. Young, and J. C. Byrd Fc{gamma}RIIIa and Fc{gamma}RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia Blood, February 15, 2004; 103(4): 1472 - 1474. [Abstract] [Full Text] [PDF] A. R. Jazirehi and B. Bonavida Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis Mol. Cancer Ther., January 1, 2004; 3(1): 71 - 84. [Abstract] [Full Text] C. F. Eisenbeis, M. A. Caligiuri, and J. C. Byrd Rituximab: Converging Mechanisms of Action in Non-Hodgkin's Lymphoma? Clin. Cancer Res., December 1, 2003; 9(16): 5810 - 5812. [Full Text] [PDF] W.-K. Weng and R. Levy Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma J. Clin. Oncol., November 1, 2003; 21(21): 3940 - 3947. [Abstract] [Full Text] [PDF] H. T. C. Chan, D. Hughes, R. R. French, A. L. Tutt, C. A. Walshe, J. L. Teeling, M. J. Glennie, and M. S. Cragg CD20-induced Lymphoma Cell Death Is Independent of Both Caspases and Its Redistribution into Triton X-100 Insoluble Membrane Rafts Cancer Res., September 1, 2003; 63(17): 5480 - 5489. [Abstract] [Full Text] [PDF] M. Coleman, D. M. Goldenberg, A. B. Siegel, J. C. Ketas, M. Ashe, J. M. Fiore, and J. P. Leonard Epratuzumab: Targeting B-Cell Malignancies through CD22 Clin. Cancer Res., September 1, 2003; 9(10): 3991S - 3994. [Abstract] [Full Text] [PDF] N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo J. Immunol., August 1, 2003; 171(3): 1581 - 1587. [Abstract] [Full Text] [PDF] J. L. Aron, M. R. Parthun, G. Marcucci, S. Kitada, A. P. Mone, M. E. Davis, T. Shen, T. Murphy, J. Wickham, C. Kanakry, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein Blood, July 15, 2003; 102(2): 652 - 658. [Abstract] [Full Text] [PDF] R. Bannerji, S. Kitada, I. W. Flinn, M. Pearson, D. Young, J. C. Reed, and J. C. Byrd Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance J. Clin. Oncol., April 15, 2003; 21(8): 1466 - 1471. [Abstract] [Full Text] [PDF] F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF] A. D. Kennedy, M. D. Solga, T. A. Schuman, A. W. Chi, M. A. Lindorfer, W. M. Sutherland, P. L. Foley, and R. P. Taylor An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab Blood, February 1, 2003; 101(3): 1071 - 1079. [Abstract] [Full Text] [PDF] J. C. Byrd, L. Smith, M. L. Hackbarth, I. W. Flinn, D. Young, J. H. Proffitt, and N. A. Heerema Interphase Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia May Predict Response to Rituximab Cancer Res., January 1, 2003; 63(1): 36 - 38. [Abstract] [Full Text] [PDF] W. L. Carroll, D. Bhojwani, D.-J. Min, E. Raetz, M. Relling, S. Davies, J. R. Downing, C. L. Willman, and J. C. Reed Pediatric Acute Lymphoblastic Leukemia Hematology, January 1, 2003; 2003(1): 102 - 131. [Abstract] [Full Text] [PDF] J. C. Byrd, B. L. Peterson, V. A. Morrison, K. Park, R. Jacobson, E. Hoke, J. W. Vardiman, K. Rai, C. A. Schiffer, and R. A. Larson Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood, January 1, 2003; 101(1): 6 - 14. [Abstract] [Full Text] [PDF] I. M. Pedersen, S. Kitada, L. M. Leoni, J. M. Zapata, J. G. Karras, N. Tsukada, T. J. Kipps, Y. S. Choi, F. Bennett, and J. C. Reed Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1 Blood, August 13, 2002; 100(5): 1795 - 1801. [Abstract] [Full Text] [PDF] N. E. Kay, T. J. Hamblin, D. F. Jelinek, G. W. Dewald, J. C. Byrd, S. Farag, M. Lucas, and T. Lin Chronic Lymphocytic Leukemia Hematology, January 1, 2002; 2002(1): 193 - 213. [Abstract] [Full Text]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020